Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04328961 · ClinicalTrials.gov registry record · Phase 2
Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)
A Phase 2 study, sponsored by University of Washington.
- Completed
- Registry status
- Phase 2
- Development phase
- 943
- Enrollment target
NCT04328961: Completed Phase 2 study, sponsored by University of Washington.
NCT04328961 is a Phase 2 study that has completed, run by University of Washington. The registered enrollment target is 943 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (609% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04328961, a Phase 2 study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 943 participants
- Enrollment target
Study Summary
This is a clinical study for the prevention of SARS-CoV-2 infection in adults exposed to the virus. This study will enroll up to 2000 asymptomatic men and women 18 to 80 years of age (inclusive) who are close contacts of persons with laboratory confirmed SARS-CoV-2 or clinically suspected COVID-19. Eligible participants will be enrolled and randomized to receive the intervention or placebo at the level of the household (all eligible participants in one household will receive the same intervention).
Primary Outcome
Polymerase chain reaction (PCR) confirmed severe acute respiratory syndrome coronavirus 2 of the genus Betacoronavirus (SARS-CoV-2) infection from self-collected samples collected daily for 14 days
Interventions
- DRUG Ascorbic Acid
- DRUG Hydroxychloroquine Sulfate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 943 participants |
| Start Date | 2020-03-31 |
| Est. Completion | 2020-10-08 |
| Phase | Phase 2 |
What the finished NCT04328961 record still lists
NCT04328961 is an interventional study that assigns participants to a tested intervention. The registered 943 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (609% higher).
The record links to 0 conditions, and to 2 interventions - of which Ascorbic Acid is the first listed.
NCT04328961 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04328961 about?
NCT04328961 is a clinical study titled "Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)". This is a clinical study for the prevention of SARS-CoV-2 infection in adults exposed to the virus. This study will enroll up to 2000 asymptomatic men and women 18 to 80 years of age (inclusive) who are close contacts of persons with laboratory confirmed SARS-CoV-2 or clinically suspected COVID-19. ...
What is the current status of trial NCT04328961?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 943 participants. The study started on 2020-03-31. Estimated completion is 2020-10-08.
What interventions are being tested in trial NCT04328961?
The interventions under investigation include: Ascorbic Acid (DRUG), Hydroxychloroquine Sulfate (DRUG).
Who is sponsoring clinical trial NCT04328961?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04328961's enrollment target sits among peer trials
943 29th of 2000 higher than 1,972 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05020236 · 944 participants · Phase 3
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
- NCT06808334 · 942 participants
CLAiR Pivotal Study
- NCT07190209 · 942 participants · Phase 3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
- NCT07190222 · 942 participants · Phase 3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI